Refine by
Harvesting System Articles & Analysis
40 news found
Stable isotope labeling consists of using non-radioactive isotopes as tracers in biochemical systems. The most obvious benefit is the non-hazardous nature of the label and the minimized need for protective measures, which could greatly free researchers from the fatigue and stress that occur when working with hazardous materials. ...
Antibody-based systems are known to underperform for isolating Circulating Tumor Cells (CTC) due to low or lack of markers expression in critical subsets of CTC. ...
Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor Cells (CTC). The ...
About ImmCelz ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells. After the patient's harvested cells are incubated with the Company's cell-free reprogramming "cocktail", the cells are re-injected back into the patient. These "supercharged" ...
3DBio Therapeutics (3DBio), a clinical-stage regenerative medicine company, and the Microtia-Congenital Ear Deformity Institute announced they have conducted a human ear reconstruction using the AuriNovo™ implant, an investigational, patient-matched, 3D-bioprinted living tissue ear implant. The groundbreaking reconstructive procedure in the first-in-human Phase 1/2a clinical trial is ...
Financial Highlights and Recent Updates: Reported commercial revenue, which excludes BARDA revenue, of $7.4 million a 61% increase compared to $4.6 million in the corresponding period in the prior year Reported total revenue, which includes BARDA revenue, of $7.5 million compared to $8.8 million in the corresponding period in the prior year, which included $4.1 million in BARDA revenue In ...
Wines, for instance, if they are not ecologically sourced, might contain sulfites, a preservative that grape growers dust over grapes in the weeks leading up to harvest. Sulfites can trigger allergy-like reactions to sensitized people, such as wheezing in those suffering from asthma, allergic rhinitis, and urticaria[3]. ...
AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, ...
About ImmCelz ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells. After the patient's harvested cells are incubated with the Company's cell-free reprogramming "cocktail", the cells are re-injected back into the patient. These "supercharged" ...
Seattle, WA, April 13, 2022 - Arzeda, the industry-leading Protein Design Company™, today announced the expansion of its commercial team with the appointments of Ken Barrett as Chief Business Officer and Scott Fabro as Senior Vice President of Food Ingredients. The addition of Barrett and Fabro advances the company’s growth and commercialization strategy of its portfolio of enzymes ...
ByArzeda
ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells. After the patient's harvested cells are incubated with the Company's cell-free reprogramming "cocktail", the cells are re-injected back into the patient. These "supercharged" cells ...
(NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that an abstract highlighting the clinical trial protocol utilizing the RECELL® Autologous Cell Harvesting Device (RECELL® System) to treat ...
CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in investigational cardiac cell therapy, which the company believes improves the probability of success of the treatment: a pre-procedural diagnostic for patient selection, a high target dosage of cells, and a proprietary delivery system that has been shown to be safer than other intramyocardial ...
Like many people with atrial fibrillation (AFib), Sheldon Kittelson of Clarkfield, Minnesota, felt trapped between the fear of having a stroke and the fear of spending a lifetime on blood thinners. For people with AFib, blood doesn’t flow through the heart normally, which can result in a clot forming in the left atrial appendage (LAA) that can break loose and lead to a stroke. ...
Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. The EIC funding comprises €2.5 millions in grants and up to €12.5 millions in equity and will support Xeltis’ clinical trial program for its XABG device, the first-ever restorative Coronary Artery Bypass Graft (CABG). XABG is a restorative, ...
The publication provides detailed analysis of a tendon biopsy taken from a 66-year-old patient 10 weeks after his own stem cells were harvested and injected into his damaged shoulder tendon using InGeneron’s Transpose® RT System. ...
Aker BioMarine, a global biotech innovator and world-leading supplier of krill, announces two new talents on the Human Nutrition team. Katina Handeland, PhD., and Yunpeng Ding, PhD. have both joined Aker BioMarine as Directors for Research & Development (R&D). They will be responsible for research within the company’s human health and nutrition department. “We are thrilled to ...
INBRAIN Neuroelectronics, a company at the intersection of medtech, deeptech and digital health dedicated to developing the world’s first graphene-based intelligent neuroelectronic system, today announced a collaboration with Merck, a leading science and technology company. ...
Surgical resection of the local disease provides the greatest chance of cure, yet, approximately 80% of resected patients die with the overwhelming pattern of recurrence being systemic. Thus, understanding the mechanisms of the underlying nature of systemic disease after margin-free resections will guide the development of more effective therapeutic strategies. ...
Origin by Ocean’s vision is to build a new value chain around the eutrophication problem of oceans – by harvesting algae from the Baltic Sea and turning algae-based biomass into sustainable ingredients. These ingredients are used in production of everyday consumer goods such as food, beverage, cosmetics and pharmaceuticals. Seaweed’s natural building blocks give algae a wide ...